Mutational Switch-Backs Can Accelerate Evolution of Francisella to a Combination of Ciprofloxacin and Doxycycline

Simple item page
dc.citation.articleNumber904822en_US
dc.citation.journalTitleFrontiers in Microbiologyen_US
dc.citation.volumeNumber13en_US
dc.contributor.authorMehta, Heer H.en_US
dc.contributor.authorIbarra, Daviden_US
dc.contributor.authorMarx, Christopher J.en_US
dc.contributor.authorMiller, Craig R.en_US
dc.contributor.authorShamoo, Yousifen_US
dc.date.accessioned2022-06-08T15:58:53Zen_US
dc.date.available2022-06-08T15:58:53Zen_US
dc.date.issued2022en_US
dc.description.abstractCombination antimicrobial therapy has been considered a promising strategy to combat the evolution of antimicrobial resistance. Francisella tularensis is the causative agent of tularemia and in addition to being found in the nature, is recognized as a threat agent that requires vigilance. We investigated the evolutionary outcome of adapting the Live Vaccine Strain (LVS) of F. tularensis subsp. holarctica to two non-interacting drugs, ciprofloxacin and doxycycline, individually, sequentially, and in combination. Despite their individual efficacies and independence of mechanisms, evolution to the combination arose on a shorter time scale than evolution to the two drugs sequentially. We conducted a longitudinal mutational analysis of the populations evolving to the drug combination, genetically reconstructed the identified evolutionary pathway, and carried out biochemical validation. We discovered that, after the appearance of an initial weak generalist mutation (FupA/B), each successive mutation alternated between adaptation to one drug or the other. In combination, these mutations allowed the population to more efficiently ascend the fitness peak through a series of evolutionary switch-backs. Clonal interference, weak pleiotropy, and positive epistasis also contributed to combinatorial evolution. This finding suggests that the use of this non-interacting drug pair against F. tularensis may render both drugs ineffective because of mutational switch-backs that accelerate evolution of dual resistance.en_US
dc.identifier.citationMehta, Heer H., Ibarra, David, Marx, Christopher J., et al.. "Mutational Switch-Backs Can Accelerate Evolution of Francisella to a Combination of Ciprofloxacin and Doxycycline." <i>Frontiers in Microbiology,</i> 13, (2022) Frontiers Media S.A.: https://doi.org/10.3389/fmicb.2022.904822.en_US
dc.identifier.digitalfmicb-13-904822en_US
dc.identifier.doihttps://doi.org/10.3389/fmicb.2022.904822en_US
dc.identifier.urihttps://hdl.handle.net/1911/112454en_US
dc.language.isoengen_US
dc.publisherFrontiers Media S.A.en_US
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleMutational Switch-Backs Can Accelerate Evolution of Francisella to a Combination of Ciprofloxacin and Doxycyclineen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fmicb-13-904822.pdf
Size:
2.3 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
BioSciences Publications